Novo Nordisk INC.
A global healthcare company focused on diabetes and other serious chronic diseases
Based in DC
🤖
AI Overview
With $1.4M in lobbying spend across 23 quarterly filings, Novo Nordisk INC. is a significant lobbying presence. They deploy 12 individual lobbyists
$1.4M
Total Lobbying Spend
23
Quarterly Filings
1
Lobbying Firms Used
12
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2020 | $180K |
| 2021 | $240K |
| 2022 | $300K |
| 2023 | $240K |
| 2024 | $180K |
| 2025 | $240K |
Lobbying Firms
TARPLIN, DOWNS & YOUNG, LLC
What They Lobby For
- Issues related to diabetes and obesity
- Issues related to implementation of P.L. 115-97 Tax Cuts and Jobs Act of 2017
- H.R. 4710 Pharmaceutical Independence Long-Term Readiness Reform Act and related "Buy American" procurement issues.
- H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201 - Families First Coronavirus Response Act S. 3548 - CARES Act Medication affordability and access; general diabetes prevention; S. 1948/H.R. 3709 Chronic Disease Management Act and general issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases; implementation of P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act; S. 2199/H.R. 4906 Insulin Price Reduction Act; H.R. 3 Elijah Cummings Lower Drug Costs Now Act; S. 1895 Lower Health Care Costs Act; H.R. 19/S 3129 Lower Costs, More Cures Act
- H.R. 1530/S. 595 Treat and Reduce Obesity Act; H.R. 1840/S. 814 Expanding Access to DSMT Act (Diabetes Self-Management Training); Medicare Diabetes Prevention Program; issues related to podiatric services; issues related to diabetic vision loss and blindness prevention; CMS coverage of diabetes technologies/services; virtual Medicare Diabetes Prevention Program (DPP) diabetes self-management education; issues related to Medicare Part D; issues related to International Price Indexing (IPI)/reference pricing in Medicare; H.R. 107 related to maximum Medicaid rebates; Medicare Part D Rebate Rule; 6 Protected Classes in Medicare Part D; S.2543 Prescription Drug Pricing Reduction Act
- H.R. 2584/S. 1361 Preventive Health Savings Act (issues related to CBO scoring of preventive health services); "Buy American" procurement issues in PL 116-136 Coronavirus Aid, Relief, and Economic Security (CARES) Act; CMS Authority to Provide Coverage for Anti-Obesity Agents Under Part D in FY21 Labor-HHS-Education Appropriations.
- H.R. 1520 Purple Book Continuity Act of 2019; H.R. 1503 Orange Book Transparency Act of 2019; issues related to importation; issues related to 340B; H.R. 4244 MAGIC (Market Access for Generic Insulin Competition) Act to provide for a pathway for chemically synthesized insulin to be approved under an abbreviated new drug application submitted under the Federal Food, Drug, and Cosmetic Act)
- Issues related to lobbying disclosure and political participation for US affiliates in H.R. 1 For the People Act.
- Medication affordability and access; general diabetes prevention; S. 1948/H.R. 3709 Chronic Disease Management Act and general issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases; implementation of P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act; S. 2199/H.R. 4906 Insulin Price Reduction Act; H.R. 3 Elijah Cummings Lower Drug Costs Now Act; S. 1895 Lower Health Care Costs Act; H.R. 19/S. 3129 Lower Costs, More Cures Act
- H.R. 1530/S. 595 Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; H.R. 1840/S. 814 Expanding Access to DSMT Act (Diabetes Self-Management Training); Medicare Diabetes Prevention Program; issues related to podiatric services; issues related to diabetic vision loss and blindness prevention; CMS coverage of diabetes technologies/services; virtual Medicare Diabetes Prevention Program (DPP) diabetes self-management education; issues related to Medicare Part D; issues related to International Price Indexing (IPI)/reference pricing in Medicare; H.R. 107 related to maximum Medicaid rebates; Medicare Part D Rebate Rule; 6 Protected Classes in Medicare Part D; S.2543 Prescription Drug Pricing Reduction Act
Related Investigations
The Defense Lobby
Defense contractors spend millions lobbying for contracts worth billions.
Big Tech's $150M Lobbying War
Tech giants battle over AI, antitrust, privacy, and trade.
Who's Lobbying to Shape AI Policy
The AI regulation fight is the biggest lobbying battle of the decade.
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.